If there are catalysts and revenue. Remember DNDN

If there are catalysts and revenue. Remember DNDN (just sold to Valeant for a fire sale of 495 Million)? Approved product that tanked big time. There's a host of other biotechs with approved drugs or diagnostics that have never caught on. I hope that's not the case for AMBS but Gerald has yet to show us a dime from any deal. Many of us thought that Lympro would have had customers ready to go upon launch due to the road show last year but again, Gerald proved us wrong. We still have no idea what the first deal is worth if anything. My guess is that Gerald cut Anavex a steal of a deal and doesn't want it known so that AMBS doesn't screw itself when negotiating bigger deals. But I am willing to bet if the details were known, many on here would be disappointed.

My Agenda: To see Amarantus prosper so I can make a nice return on my investment.